Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 37, Issue 2, 2010, Pages 157-177

  Jacqmin, Philippe ^a   McFadyen, Lynn ^b   Wade, Janet R ^a  

^a Exprimo NV   (Belgium)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Basic reproductive ratio (R0); Circular systems; Disease modelling; PK PD; Proliferative systems; Reproduction Minimum Inhibitory Concentration (RMIC)

Indexed keywords

ARTICLE; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; IC 50; LIFESPAN; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROGENY; STEADY STATE;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; HUMANS; LOGISTIC MODELS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PHARMACOKINETICS; PHARMACOLOGY; VIRAL LOAD; VIRUS DISEASES;

EID: 77953544231     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-010-9151-7     Document Type: Article

References (38)

1. Grasela TH, Dement CW, Kolterman O.G., Fineman MS, Grasela DM, Honig P., Antal E.J., Bjornsson TD, Loh E. (2007) Pharmacometrics and the transition to model-based development. Clin Pharmacol Ther 82:137-142
2. Lalonde RL, Kowalski KG, Hutmacher M.M., Ewy W., Nichols DJ, Milligan PA, Corrigan BW, Lockwood P.A., Marshall SA, Benincosa LJ, Tensfeldt TG, Parivar K., Amantea M., Glue P, Koide H, Miller R (2007) Model-based drug development. Clin Pharmacol Ther 82:21-32
3. Nestorov I (2003) Whole body pharmacokinetic models. Clin Pharmacokinet 42(10):883-908
4. de Winter W., DeJongh J., Post T., Ploeger B, Urquhart R., Moules I., Eckland D, Danhof M. (2006) A mechanism based disease progression model for comparison of long term effects of pioglitazone, metformin and glicazide on disease processes underlying type 2 diabetes mellitus. J Pharmacokinet Pharmacodyn 33:313-343
5. Ribbing J (2007) Covariate model building in non-linear mixed effects models. Acta Universitatis Upsaliensis. Digital comprehensive summaries of Uppsala dissertations from the Faculty of Pharmacy 59, Uppsala, 77 pp. ISBN 978-91-554-6916-3
6. Perelson AS (2002) Modelling viral and immune system dynamics. Nat Rev Immunol 2:28-36
7. Jonsson EN, Macintyre F., James I., Krams M, Marshall S. (2005) Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition. Pharm Res 22(8):1236-1246
8. Danhof M, de Jongh J, De Lange ECM, Della Pasqua O, Ploeger BA, Voskuyl RA (2007) Mechanism-based pharmacokinetic/pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 47:357-400
9. Holford NHG, Chan PLS, Nutt JG, Kieburtz K., Shoulson I., Parkinson Study Group (2006) Disease progression and pharmacodynamics in Parkinson's disease - evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn 33:281-312
10. Wilson I (2007) Top-down versus bottom-up - rediscovering physiology via systems biology? Mol Syst Biol 3: Article number 113. doi:10.1038/msb4100154 (Pubitemid 46801776)
11. Chan PL, Holford N.H. (2001) Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol 41:625-659
12. Lotka AJ (1925) Elements of physical biology. Williams & Wilkins Co, Baltimore
13. Volterra V (1926) Variazioni e fluttuazioni del numero d'individui in specie animali conviventi. Mem R Accad Naz dei Lincei Ser VI, vol 2
14. Nowak MA, Bonhoeffer S., Shaw G.M., May R.M. (1997) Anti-viral drug treatment: dynamics of resistance in free virus and infected cell population. J Theor Biol 184:203-217
15. Bonhoeffer S, May RM, Shaw G.M., Nowak M.A. (1997) Virus dynamics and drug therapy. Proc Natl Acad Sci USA 94:6971-6976
16. Bonhoeffer S (1998) Models of viral kinetics and drug resistance in HIV-1 infection. AIDS Patient Care STDS 12:769-774
17. Funk GA, Fischer M., Joos B., Opravil M, Günthard H, Ledergerber B., Bonhoeffer S. (2001) Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells. J Acquir Immune Defic Syndr 26(5):397-404
18. Heffernan JM, Smith RJ, Wahl L.M. (2005) Perspectives on the basic reproductive ratio. J R Soc Interface 2(4):281-293
19. Hill AV (1910) The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol 40:iv-vii
20. Rosario MC, Poland B., Sullivan J., Westby M, van der Ryst E (2006) A pharmacokinetic-pharma- codynamic model to optimize the phase IIa development program of maraviroc. J Acquir Immune Defic Syndr 42(2):183-191
21. Gibaldi M, Perrier D. (1982) Chapter 1. In: Pharmacokinetics (2nd edn). Marcel Dekker Inc., New York
22. Jacqmin P, McFadyen L., Wade J.R. (2008) A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc. Br J Clin Pharmacol 65(Suppl 1):95-106
23. Wahl LM, Nowak M.A. (2000) Adherence and drug resistance: predictions for therapy outcome. Proc Biol Sci 267(1445):835-843
24. Huang Y, Liu D., Wu H. (2006) Hierarchical bayesian methods for estimation of parameters in a longitudinal HIV dynamic system. Biometrics 62:413-423
25. Ferguson NM, Donnelly CA, Hooper J., Ghani A.C., Fraser C., Bartley LM, Rode RA, Vernazza P., Lapins D., Mayer S.L. (2005) Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients. J R Soc Interface 2:349-363
26. Wu H, Huang Y., Acosta E.P., Park JG, Yu S, Rosenkranz SL, Kuritzkes D.R., Eron JJ, Perelson AS, Gerber J.G. (2006) Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. J Pharmacokinet Pharmacodyn 33(4):399-419
27. Lepri AC, Miller V., Phillips A.N., Rabenau H., Sabin CA, Taszewski S. (2001) The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4 ± 8 viral load. AIDS 15:47-54
28. Knolle PA, Kremp S., Höhler T, Krummenauer F., Schirmacher P, Gerken G. (1998) Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up. J Viral Hepat 5:399-406
29. Kessler HH, Pierer K., Santner B.I., Vellimedu SK, Stelzl E, Marth E., Fickert P., Stauber R.E. (1998) Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy. J Hum Virol 1:314-319
30. Ampurdanés S., Olmedo E., Maluenda M.D., Forns X., López-Labrador FX, Costa J, Sánchez-Tapias JM, de Anta MT, Rodés J (1996) Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. J Hepatol 25:827-832
31. Kitchen CM, Kitchen SG, Dubin J.A., Gottlieb M.S. (2001) Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome. Clin Infect Dis 33:466-472
32. Gunderson BW, Ross GH, Ibrahim K.H., Rotschafer J.C. (2001) What do we really know about antibiotic pharmacodynamics? Pharmacotherapy 21:302S-318S
33. Karlsson MO, Molnar V., Bergh J., Freijs A, Larsson R. (1998) A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 63:11-25
34. Labbé L, Verotta D (2006) A non-linear mixed effect dynamic model incorporating prior exposure and adherence to treatment to describe long-term therapy outcome in HIV-patients. J Pharmacokinet Pharmacodyn 33(4):519-542
35. Huang Y, Rosenkranz SL, Wu H. (2003) Modeling HIV dynamics and antiviral responses with consideration of time-varying drug exposures, sensitivities and adherence. Math Biosci 184:165-186
36. Csajka C, Verotta D. (2006) Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn 33(3):227-279
37. Phillips AN, Youle M., Johnson M., Loveday C. (2001) Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development. AIDS 15(17):2211-2220
38. Rong L, Feng Z., Perelson A.S. (2007) Emergence of HIV-1 drug resistance during antiretroviral treatment. Bull Math Biol 69(6):2027-2060